Bakhtyar Ali.
Founder working on mRNA therapeutics and the infrastructure around them. Interested in what happens when biology is treated less like an academic discipline and more like a set of tools you can point at something.
Building
Amrixa Pharmaceuticals
Founder & CEOmRNA therapeutics. Programmable medicines against diseases the current pharmaceutical stack has priced out or given up on.
Nucleic Labs
FounderA biotech incubator network — shared wetlab infrastructure, capital, and a bench for founders shipping wet biology at software cadence.
Other
8/26
Fellow, New Science
Self-replicating mRNA and genetic medicines grantee.
8/26
Fellow, Longevity Biotech Fellowship
Self-replicating mRNA to solve aging, LBF8.
6/26
GPT 5.5-5.6 Bio Redteaming, OpenAI
External biosecurity testing under Bio Bug Bounty program.
5/26
Next-Gen BioLeaders, SynBioBeta
NGB, Cohort 1 (Profile)
Thesis
Biology is the most underpriced technology of the century. The bottleneck is not ideas — it is the cost of iteration, the shape of capital, and the number of serious people in the room. I am trying to move each of those, in that order.
Elsewhere